ELDN - Eledon Pharmaceuticals, Inc. Stock Price, Fair Value and News

$3.52+0.08 (+2.33%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ELDN Price Action

Last 7 days

-3.6%

Last 30 days

-21.9%

Last 90 days

-19.3%

Trailing 12 Months

87.2%

ELDN RSI Chart

ELDN Valuation

Market Cap

210.5M

Price/Earnings (Trailing)

-5.82

Price/Sales (Trailing)

1.6K

EV/EBITDA

-5.31

Price/Free Cashflow

-4.45

ELDN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ELDN Fundamentals

ELDN Revenue

Revenue (TTM)

136.0K

ELDN Earnings

Earnings (TTM)

-36.2M

Earnings Growth (Yr)

-48.23%

Earnings Growth (Qtr)

-157.97%

ELDN Profitability

EBT Margin

-26288.97%

Return on Equity

-30.63%

Return on Assets

-20.4%

Free Cashflow Yield

-22.46%

ELDN Investor Care

Shares Dilution (1Y)

146.93%

Diluted EPS (TTM)

-1.12

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2017	136.0K	0	0	0
2016	188.0K	212.0K	196.0K	164.0K
2015	168.0K	170.0K	172.0K	174.0K
2014	0	0	0	166.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

CEO	Dr. David-Alexandre C. Gros M.D., Ph.D.
WEBSITE	https://eledon.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	17

Eledon Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Eledon Pharmaceuticals, Inc.? What does ELDN stand for in stocks?

ELDN is the stock ticker symbol of Eledon Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eledon Pharmaceuticals, Inc. (ELDN)?

As of Fri Mar 21 2025, market cap of Eledon Pharmaceuticals, Inc. is 210.46 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ELDN stock?

You can check ELDN's fair value in chart for subscribers.

Is Eledon Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether ELDN is over valued or under valued. Whether Eledon Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Eledon Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ELDN.

What is Eledon Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 21 2025, ELDN's PE ratio (Price to Earnings) is -5.82 and Price to Sales (PS) ratio is 1.6 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ELDN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eledon Pharmaceuticals, Inc.'s stock?

In the past 10 years, Eledon Pharmaceuticals, Inc. has provided -0.475 (multiply by 100 for percentage) rate of return.